Manila Times Business
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), a serious complication affecting 35,000 U.S. patients annually, with no approved FDA-approved targeted therapiesDual-Purpose Synergy - Planned Phase 2a proof-of-concept trial expected to generate safety, renal injury signals, and 12-LOX pathway biology in high-risk cardi
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Twenty-six years later: Finally seeing the first sunrise at Pusan Point
Just now
BSB Junrose strengthens portfolio for hybrid, EV, and conventional vehicles
Just now
FAW trucks launches 'Wheels of Hope' outreach for Rizal school
Just now
100x Leverage, No KYC, $50 Welcome Bonus, and Double Deposit Bonus - Trade Crypto Futures on BexBack
Just now